Understanding Sanofi's Voting Rights and Shares
Sanofi, a prominent French pharmaceutical company, plays a significant role in the global healthcare landscape. The company's commitment to transparency and governance is evident in its regular disclosures. Here we delve into the critical information regarding the total number of issued shares and voting rights as required by French law.
Company Overview
Sanofi operates as a société anonyme with a robust registered capital of €2,467,152,142. This substantial foundation empowers Sanofi to engage actively in innovation and research, aimed at providing groundbreaking healthcare solutions. With its registered office located in Paris, the company is well-positioned at the heart of Europe’s business and regulatory frameworks. This strategic location facilitates efficient operations and accessibility to diverse markets.
Current Data on Shares and Voting Rights
As of February 28, 2025, a significant milestone is recorded in the company's operational metrics. Sanofi has issued a total of 1,263,132,721 shares. Significantly, the number of real voting rights, which excludes treasury shares, stands at 1,354,221,504. Furthermore, when considering treasury shares, the theoretical number of voting rights is reported to be 1,396,197,561. This data highlights Sanofi’s strong shareholder base and their engagement in corporate decisions.
The Importance of Voting Rights
Voting rights play a crucial role in corporate governance, allowing shareholders a voice in decision-making processes. For Sanofi’s stakeholders, understanding the voting rights is essential to engage actively in the company’s future directions. Transparent reporting fosters trust and reinforces the company's commitment to fair governance practices, ensuring that all shareholders feel represented and heard.
Compliance with Regulatory Standards
Sanofi provides this important information in compliance with article L. 233-8 II of the Code de commerce and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers. This adherence not only demonstrates regulatory compliance but also reaffirms Sanofi’s dedication to maintaining high standards of corporate accountability.
Investor Relations and Communication
Effective communication is a cornerstone of successful investor relations. Sanofi’s Investor Relations Department is committed to providing accurate and timely information to current and potential investors. The department encourages inquiries and engagement through its designated email: investor.relations@sanofi.com. This openness facilitates a deeper connection with shareholders.
Further Information and Resources
Additional details regarding Sanofi’s shares and voting rights can be found on their official website under the "Regulated Information in France" section. This online availability of critical data makes it easier for shareholders and interested parties to stay informed and engaged with the company’s governance practices.
Frequently Asked Questions
What is Sanofi’s total number of issued shares?
As of February 28, 2025, Sanofi has issued a total of 1,263,132,721 shares.
How many real voting rights does Sanofi have?
The number of real voting rights, excluding treasury shares, is 1,354,221,504.
What are theoretical voting rights, including treasury shares?
The theoretical number of voting rights, including treasury shares, is 1,396,197,561.
Where can I find more information about Sanofi’s governance?
Further information is available on Sanofi's official website under the "Regulated Information in France" section.
How can I contact Sanofi’s Investor Relations?
You can contact Sanofi’s Investor Relations Department via email at investor.relations@sanofi.com.
